Skip to product information
1 of 1
Out of Stock

Wegovy (Semaglutide) Injection Pen 0.25 mg, 1 Ct - Novo Nordisk

Wegovy (Semaglutide) Injection Pen 0.25 mg, 1 Ct - Novo Nordisk

Regular price PKR 31,945
Regular price Sale price PKR 31,945
Out of Stock
Pack Size: 1 x 1.5mL pen & 4 disposable needles
Wegovy 0.25 mg is a prescription glucagon‑like peptide‑1 (GLP‑1) receptor agonist used as the initial starting dose for chronic weight management. It is indicated for adults with obesity (BMI ≥30...  Read More
SKU: 05712249132774
Availability: In Stock
Country: Pakistan
View full details

Description

Wegovy 0.25 mg is a prescription glucagon‑like peptide‑1 (GLP‑1) receptor agonist used as the initial starting dose for chronic weight management. It is indicated for adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight‑related comorbidity, and to reduce cardiovascular risk in adults with established cardiovascular disease and BMI ≥27 kg/m²

  • Initial Dose for Safe Titration: The 0.25 mg once‑weekly dose is the recommended starting dose for the first 4 weeks of treatment, allowing your body to gradually adjust to semaglutide and minimize common gastrointestinal side effects (nausea, vomiting, diarrhea) before dose escalation
  • Foundation for Clinically Proven Weight Loss: While the 0.25 mg dose itself does not produce significant weight loss, it is the essential first step in the 16‑week titration schedule leading to the 2.4 mg maintenance dose, which achieved a mean weight loss of up to 15.6% in clinical trials
  • Reduces Cardiovascular Risk (as part of full regimen): When continued to the 2.4 mg maintenance dose, semaglutide is proven to reduce the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in adults with established cardiovascular disease and BMI ≥27 kg/m²
  • Once‑Weekly, Flexible Dosing: The 0.25 mg pen is administered subcutaneously once weekly, at any time of day, with or without meals – convenient and easy to incorporate into your routine. After 4 weeks, your doctor will guide you to the next titration dose (0.5 mg)

Composition
Each prefilled pen contains 1 mg semaglutide in 1.5 mL (0.68mg/mL)

Directions for Use

  • Use as prescribed by the physician.

Legal Disclaimer

Unless expressly indicated in the product description, MyVitaminStore.pk is not the manufacturer of the products sold on our website. While we work to ensure that product information on our website is correct, manufacturers may alter their product information. Actual product packaging and materials may contain more and/or different information than shown on our website. If you have any specific product queries, please contact the manufacturer. For medicinal products, content on our website is not intended to be used to diagnose, treat, cure, or prevent any disease or health condition or to substitute advice given by medical practitioners, pharmacists or other licensed health care professionals. You should contact your health care provider immediately if you suspect that you have a medical problem. You should always read the labels, warnings and instructions provided with the product before using or consuming it and not solely rely on the information presented on our website.

Collapsible content

Product Overview

Wegovy 0.25 mg is a prescription glucagon‑like peptide‑1 (GLP‑1) receptor agonist used as the initial starting dose for chronic weight management. It is indicated for adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight‑related comorbidity, and to reduce cardiovascular risk in adults with established cardiovascular disease and BMI ≥27 kg/m²

  • Initial Dose for Safe Titration: The 0.25 mg once‑weekly dose is the recommended starting dose for the first 4 weeks of treatment, allowing your body to gradually adjust to semaglutide and minimize common gastrointestinal side effects (nausea, vomiting, diarrhea) before dose escalation
  • Foundation for Clinically Proven Weight Loss: While the 0.25 mg dose itself does not produce significant weight loss, it is the essential first step in the 16‑week titration schedule leading to the 2.4 mg maintenance dose, which achieved a mean weight loss of up to 15.6% in clinical trials
  • Reduces Cardiovascular Risk (as part of full regimen): When continued to the 2.4 mg maintenance dose, semaglutide is proven to reduce the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in adults with established cardiovascular disease and BMI ≥27 kg/m²
  • Once‑Weekly, Flexible Dosing: The 0.25 mg pen is administered subcutaneously once weekly, at any time of day, with or without meals – convenient and easy to incorporate into your routine. After 4 weeks, your doctor will guide you to the next titration dose (0.5 mg)

Composition
Each prefilled pen contains 1 mg semaglutide in 1.5 mL (0.68mg/mL)

Directions for Use

  • Use as prescribed by the physician.

Legal Disclaimer

Unless expressly indicated in the product description, MyVitaminStore.pk is not the manufacturer of the products sold on our website. While we work to ensure that product information on our website is correct, manufacturers may alter their product information. Actual product packaging and materials may contain more and/or different information than shown on our website. If you have any specific product queries, please contact the manufacturer. For medicinal products, content on our website is not intended to be used to diagnose, treat, cure, or prevent any disease or health condition or to substitute advice given by medical practitioners, pharmacists or other licensed health care professionals. You should contact your health care provider immediately if you suspect that you have a medical problem. You should always read the labels, warnings and instructions provided with the product before using or consuming it and not solely rely on the information presented on our website.

Product Overview

Wegovy 0.25 mg is a prescription glucagon‑like peptide‑1 (GLP‑1) receptor agonist used as the initial starting dose for chronic weight management. It is indicated for adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight‑related comorbidity, and to reduce cardiovascular risk in adults with established cardiovascular disease and BMI ≥27 kg/m²

  • Initial Dose for Safe Titration: The 0.25 mg once‑weekly dose is the recommended starting dose for the first 4 weeks of treatment, allowing your body to gradually adjust to semaglutide and minimize common gastrointestinal side effects (nausea, vomiting, diarrhea) before dose escalation
  • Foundation for Clinically Proven Weight Loss: While the 0.25 mg dose itself does not produce significant weight loss, it is the essential first step in the 16‑week titration schedule leading to the 2.4 mg maintenance dose, which achieved a mean weight loss of up to 15.6% in clinical trials
  • Reduces Cardiovascular Risk (as part of full regimen): When continued to the 2.4 mg maintenance dose, semaglutide is proven to reduce the risk of major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20% in adults with established cardiovascular disease and BMI ≥27 kg/m²
  • Once‑Weekly, Flexible Dosing: The 0.25 mg pen is administered subcutaneously once weekly, at any time of day, with or without meals – convenient and easy to incorporate into your routine. After 4 weeks, your doctor will guide you to the next titration dose (0.5 mg)

Composition
Each prefilled pen contains 1 mg semaglutide in 1.5 mL (0.68mg/mL)

Directions for Use

  • Use as prescribed by the physician.

Legal Disclaimer

Unless expressly indicated in the product description, MyVitaminStore.pk is not the manufacturer of the products sold on our website. While we work to ensure that product information on our website is correct, manufacturers may alter their product information. Actual product packaging and materials may contain more and/or different information than shown on our website. If you have any specific product queries, please contact the manufacturer. For medicinal products, content on our website is not intended to be used to diagnose, treat, cure, or prevent any disease or health condition or to substitute advice given by medical practitioners, pharmacists or other licensed health care professionals. You should contact your health care provider immediately if you suspect that you have a medical problem. You should always read the labels, warnings and instructions provided with the product before using or consuming it and not solely rely on the information presented on our website.